James A Geraghty
CIK 1239746 · Senior Vice President · last filed 2026-07-02
James A Geraghty is a Senior Vice President who has filed 100 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for FULC, was dated Jul 2, 2026. Across all open-market trades the lifetime net is −$484.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $907.1K across reported positions. 14 SEC filings were submitted jointly with COLUMBIA LABORATORIES INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GENZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
167 SIDNEY STREET
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FULC | Director | 90,714 | $3.77 | $342.0K | $91.6K | 9 | 2026-07-02 |
| VYGR | Director | 76,588 | $2.45 | $187.6K | $113.1K | 13 | 2026-06-11 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Director | 0 | $13.60 | $0 | $105.7K | 13 | 2024-12-12 |
| Orchard Therapeutics plc (ORTX) Delisted | Director | 0 | $16.70 | $0 | $0 | 5 | 2024-01-24 |
| Aceragen, Inc. (IDRA) Delisted | Director | 7,032 | $7.22 | $50.8K | $817.0K | 25 | 2022-06-27 |
| JUNIPER PHARMACEUTICALS INC (JNP) Delisted | Director | 0 | — | — | $455.0K | 13 | 2018-08-15 |
| GENZ | Senior Vice President | 9,845 | $38.34 | $377.5K | -$2.08M | 7 | 2011-04-06 |
| GTC BIOTHERAPEUTICS INC (GTCB) Delisted | Director | 19,163 | — | — | $8.7K | 15 | 2010-01-05 |
Recent Filings
100 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | FULC | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | VYGR | Grant (A) | — | $0 | EDGAR |
| 2025-06-30 | FULC | Grant (A) | — | $0 | EDGAR |
| 2025-06-04 | VYGR | Grant (A) | — | $0 | EDGAR |
| 2024-12-12 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Disp (D) | −1 | -$0 | EDGAR |
| 2024-10-28 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Buy (P) | +1 | $1 | EDGAR |
| 2024-06-18 | FULC | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | VYGR | Grant (A) | — | $0 | EDGAR |
| 2024-01-24 | Orchard Therapeutics plc (ORTX) Delisted | Disp (D) | −44,391 | $0 | EDGAR |
| 2023-06-29 | FULC | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.